CYCLACEL PHARMACEUTICALS, INC.
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
|April 16, 2020|
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
|Re:||Cyclacel Pharmaceuticals, Inc.|
Registration Statement on Form S-1
Filed on March 13, 2020, as amended on April 14, 2020
File No. 333-237180
Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-1 be accelerated to Monday, April 20, 2020, at 4:30 p.m., EST, or as soon as thereafter practicable.
Any questions should be addressed to Joel I. Papernik, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center, 666 Third Avenue, New York, New York, telephone (212) 692-6774.
Thank you for your attention to this matter.
|Very truly yours,|
|Cyclacel Pharmaceuticals, Inc.|
|/s/ Spiro Rombotis|
|Chief Executive Officer|
|cc:||Cyclacel Pharmaceuticals, Inc.|